#Zentiva #Brussels #Belgium #Affordable Medicines #EU Directives

Zentiva's Urgent Call for the Urban Wastewater Treatment Directive Reform

In a recent annual meeting held in Brussels, Medicines for Europe brought together key policymakers and industry leaders to discuss essential healthcare directives, particularly focusing on the Urban Wastewater Treatment Directive (UWWTD). Zentiva's CEO, Steffen Saltofte, highlighted the pressing need for a strategic pause, repair, and relaunch of this directive, which, if left unchanged, threatens the availability and affordability of essential medicines across Europe.

The Current Situation

The UWWTD has been increasingly scrutinized due to its potential adverse effects on the generics industry. As Europe grapples with geopolitical challenges and legislative simplifications, the practical implications of the directive have raised significant concerns among pharmaceutical companies like Zentiva. Saltofte noted that the current implementation is fundamentally flawed and could jeopardize both medicine affordability and supply security.

Key takeaways from the meeting included:
1. Risks of Current Implementation: The directive's existing framework, characterized by unrealistic assumptions and underestimation of associated costs by the European Commission, poses serious threats. This situation risks making essential off-patent medicines scarce, which would have detrimental impacts on patient care and public health in the long run.

2. A Viable Alternative: Zentiva advocates for an alternative model inspired by Switzerland, which demonstrates that equitable cost-sharing and phased implementation can achieve environmental goals without impacting patient care negatively. Such a collaborative approach could ensure that public health does not suffer under the weight of environmental regulations.

3. Economic Viability of Manufacturing: Ensuring the economic sustainability of pharmaceutical manufacturing within Europe is critical. Saltofte warned that if current policies impose disproportionate financial burdens on manufacturers, production could be driven out of the EU, compromising supply resilience and undermining the EU's healthcare ambitions.

The Future of Medicines in Europe

Zentiva's approach underscores a crucial perspective: the relationship between sustainability, healthcare access, and economic viability must be meticulously balanced. Saltofte emphasized, "Sustainability is not solely environmental; it encompasses the sustainability of care. We must guarantee that everyone who relies on medicines can access them without facing prohibitive costs. Health must be regarded as a right, not a privilege."

Zentiva, a European company dedicated to producing high-quality, affordable medicines, has been at the forefront of advocating for accessible healthcare. Established over 500 years ago in a small pharmacy in Prague, they continue to thrive with an extensive network across over 30 countries.

With more than 5,000 employees, Zentiva is committed to maintaining its role as a reliable supplier of essential medicines while aiming for sustainable growth. The company envisions a future where healthcare accessibility and affordability remain paramount, all aligned with its core values of care, inclusivity, and innovation.

As Europe navigates these complex challenges, Zentiva's voices resonate with urgency. The need for a comprehensive re-evaluation of health directives is clear, especially as the continent seeks to fortify its healthcare system against future crises. The dialogue initiated at the Brussels meeting serves as a critical step towards realizing a healthcare framework that responsibly balances ecological considerations with the indispensable need for accessible medicines.